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a b s t r aC t
infection with Yersinia enterocolitica leads to a self-limiting 
disease, but in a small number of cases a protracted course 
can develop. the host genetic factors contributing to the 
advancement of the disease to the chronic phase are not 
known. we describe a patient suffering from an abdominal 
inflammatory mass due to chronic yersiniosis. functional 
assays revealed defects in the recognition of flagellin by 
toll-like receptor 5 (tlr5) and of muramyl dipeptide by 
nod2, leading to a defective inflammatory response to 
Yersinia enterocolitica. genetic sequencing showed that 
the patient was compound heterozygous for five different 
mutations in tlr5, while being homozygous for the 
3020insC nod2 mutation. in conclusion, we describe a 
patient in whom specific defects in the tlr5 and nod2 
recognition pathways led to chronic yersiniosis. 
K e y wor ds
Cytokine, Crohn’s disease, NOD2, TLR5, Yersinia 
i n t roduC t i on
Yersinia enterocolitica is a flagellated Gram-negative 
bacterium that is pathogenic for humans. Infection 
occurs through consumption of contaminated water 
or food, and when healthy individuals are infected, 
generally a self-limiting intestinal inflammation ensues. 
Occasionally, more serious protracted disease develops.1 
Chronic mesenteric lymphadenitis, ileitis and hepatitis 
are major manifestations of more severe yersiniosis, as are 
extra-intestinal presentations such as reactive arthritis and 
erythema nodosum.2 
Y. enterocolitica infects the Peyer’s patches and other 
elements of the mucosa-associated lymphoid tissue, and here 
the organism may persist for long periods of time. In recent 
years, many of the virulence factors of Y. enterocolitica have 
been discovered; among these the Yersinia outer proteins 
(Yop) and LcrV are the most prominent.3 Delivery of Yop 
into the cytoplasm of host cells through a type III secretion/
translocation system is crucial in the pathogenesis of the 
infection.4 LcrV is a released multifunctional molecule 
that acts as an immunomodulatory molecule by interaction 
with CD14 and Toll-like receptor (TLR) 2 and subsequent 
induction of interleukin-10 (IL-10).5 In addition to recognition 
by TLR2, other pattern recognition receptors of the innate 
immune system are likely to play a role in the interaction of 
Y. enterocolitica with the host. As Yersinia spp are flagellated 
bacteria, recognition of flagellin by TLR5 also contributes to 
the recognition by the host,6 while TLR4 is important for 
induction of apoptosis.7 NOD2, the intracellular recognition 
receptor for peptidoglycans and muramyl dipeptide (MDP)8,9 
could also be expected to play a role in the interaction 
between Y. enterocolitica and host cells.
From experiments in murine models it is known that 
interferon g (IFNg) and the cytokines responsible for its 
induction, IL-12 and IL-18, are essential for protective 
immunity against Y. enterocolitica.10-12 In addition, 
other proinflammatory cytokines such as IL-6 are also 
involved in the protective anti-Yersinia mechanisms,13 
while triggering IL-10 through an LcrV/TLR2-dependent 
mechanism is essential for virulence.14
In this paper we report the history of a patient with a 
severe chronic yersiniosis. The persistence of Yersinia 
was accompanied by a defective cytokine response to the 
micro-organisms by leucocytes isolated from the patient, 
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which was very likely responsible for the protracted 
course of the disease. We also pinpoint the defective 
cytokine response to defects in TLR5- and NOD2-mediated 
recognition of Y. enterocolitica in this patient.
pat i e n t s  a n d  M e t hods
Case report
A 28-year-old male was referred to the outpatient clinic for 
infectious diseases at the Radboud University Nijmegen 
Medical Centre. In February 2003, the patient developed 
right-sided abdominal pain followed by chills and high fever. 
He was admitted 14 days after the start of the illness. A CT 
scan revealed multiple enlarged mesenterial lymph nodes 
close to the aortic bifurcation. The immunoblot for the Y. 
enterocolitica antibodies was positive, showing specific IgG 
and IgA reactivity against Yop1, 3, 3A, 4 and 5. A presumptive 
diagnosis of Y. enterocolitica mesenterial adenitis was made, 
and subsequently the patient was treated with ciprofloxacin 
for a total of six months. Despite this treatment, the patient’s 
fever, malaise and elevated C-reactive protein persisted. An 
extensive work-up search for alternative diagnoses such 
as Whipple’s disease was fruitless. Crohn’s disease was 
unlikely as a small bowel X-ray series and colonoscopy 
revealed no abnormalities. A biopsy taken from a mesenterial 
lymph node mass yielded granulomatous inflammation with 
epitheloid cells and perilymphadenitis. No micro-organisms 
were seen and further microbiological investigations 
remained negative. As the immunoblot against Yersinia 
epitopes remained positive and his abdominal complaints 
persisted, we decided to perform positron emission 
tomography using 18F-fluorodeoxyglucose (FDG-PET), 
which revealed an FDG accumulation in the lower abdomen 
consistent with a mass with a diameter of 7 cm.
The patient started treatment with minocyclin (100 mg/
day) for additional six months. During this treatment the 
fever and complaints subsided and a subsequent FDG-PET 
showed a decrease of abdominal mass. No side effects of 
minocyclin treatment were reported.
Materials
Muramyl dipeptide, poly I:C and flagellin were purchased 
from Sigma Chemical Co (St. Louis, MO), and synthetic 
Pam3Cys from EMC Microcollections (Tübingen, Germany). 
LPS (Escherichia coli 055:B5) was purchased from Sigma, and 
repurifed as previously described.15 LcrV was kindly provided 
by Prof. J. Heesemann (Munchen, Germany). 
Isolation of peripheral blood mononuclear cells and 
cytokine stimulation
After informed consent, venous blood was drawn from 
the cubital vein of the patient (collected after minocyclin 
treatment, during a stable phase of the disease, without 
acute signs of inflammation), healthy family members and 
five healthy volunteers (all male, age 22-35 years old) into 
three 10 ml EDTA tubes (Monoject, s-Hertogenbosch, the 
Netherlands). In addition, cells isolated from four patients 
with Crohn’s disease homozygous for 3020insC NOD2 
mutation were also used as an additional control group. 
Isolation of mononuclear cells (MNC) was performed as 
described elsewhere,16 with minor modifications. The MNC 
fraction was obtained by density centrifugation of blood 
diluted 1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia 
Biotech AB, Uppsala, Sweden). Cells were washed twice in 
saline and suspended in culture medium (RPMI 1640 DM) 
supplemented with gentamicin 10 mg/ml, L-glutamine 10 
mm and pyruvate 10 mm. The cells were counted in a Coulter 
counter (Coulter Electronics, Mijdrecht, the Netherlands) and 
the number was adjusted to 5 x 106 cells/ml. 
5 x 105 MNC in a 100 ml volume were added to round-bottom 
96-wells plates (Greiner, Alphen a/d Rijn, the Netherlands) 
and incubated with either 100 ml of culture medium (negative 
control), various concentrations of heat-killed Y. enterocolitica, 
or LcrV (5 mg/ml). In addition, stimulation experiments with 
various TLR and NOD2 stimuli were performed in separate 
wells: MDP (10 mg/ml), Pam3Cys lipopeptides (1 mg/ml), poly 
I:C (50 mg/ml), purified E. coli LPS (1 ng/ml), flagellin (10 
ng/ml). After 24 hours incubating at 37°C, the supernatants 
were stored at -80°C. Cytokine concentrations were measured 
by specific commercial ELISA kits from R&D Systems 
(Minneapolis, MN).
Genotyping of TLR5 gene
Amplification of the six exons of the TLR5 gene was 
performed using 11 polymerase chain reactions (PCR). 
After DNA purification, the sequencing was performed at 
the Clinical Genetic Centre Nijmegen, Radboud University 
Nijmegen Medical Centre, using the Big Dye terminator 
version 2 Chemic (Applied Biosystems, Nieuwerkerk a/d 
IJssel, the Netherlands). The sequence was checked using 
Biology Workbench 3.2.
Genotyping of 3020insC NOD2 gene variant
Blood was collected from the patient and his family (mother, 
father, and three sisters). PCR amplification of NOD2 gene 
fragments containing the polymorphic site 3020insC was 
performed in 50 ml reaction volumes containing 100 to 200 
ng genomic DNA, as previously described.17 The 3020insC 
polymorphism was analysed by Genescan analysis on an 
ABI Prism 3100 Genetic Analyser according to the protocol 
of the manufacturer (Applied Biosystems). 
Patient consent
Written consent was given by the patient and family. The 
analysis performed in the study took place within the 
diagnostic work-up of the disease, and therefore no ethics 
commission approval was necessary.
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r e su lt s
Cytokine production induced by y. enterocolitica and lcrv 
in pbMC of healthy volunteers
In a first series of experiments we measured the cytokine 
responses of peripheral blood mononuclear cells (PBMC) 
of five human volunteers exposed to Y. enterocolitica. 
With 5 x 103 and 5 x 104 cfu/ml Y. enterocolitica, a sizeable 
cytokine response was seen, the IL-6 response being the 
most accentuated (figure 1A). Strong stimulation of IL-10 
(1444±383 pg/ml) and tumour necrosis factor (714±215 pg/
ml) by 5 x 104 cfu/ml Y. enterocolitica was also measured.
The response to LcrV in a dose range between 1.25 and 5 
mg/ml was lower for all cytokines: low amounts of IL-10 
and TNF, but a clear dose response for IL-6 (figure 1B).
pMbC responses to y. enterocolitica and tlr/nod2 ligands
Interestingly, when PBMC of the patient with 
chronic yersiniosis were exposed to whole Yersinia 
micro-organisms, a strongly blunted IL-6 response was 
observed. The IL-6 response to LcrV in the patient was 
in the normal range (figure 2A). The IL-10 response to 
LcrV was low and also did not differ between patient and 
controls (not shown). 
Based on these findings we assessed the response to 
well-defined TLR ligands. 
In these experiments we found virtually no cytokine 
response to flagellin, the ligand for TLR5, and MDP, the 
ligand for NOD2, and normal responses to ligands for 
TLR2, TLR3 and TLR4 (figure 2B). We repeated these 
studies four times, always with the same results. 
figure 1. Cytokine production induced by Y. 
enterocolitica and LcrV 
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a. freshly isolated peripheral blood mononuclear cells from human 
volunteers were stimulated with y. enterocolitica (5 x 103 and 5 x 104 
cfu/ml) (panel a) or lcrv in various concentrations (panel b), and il-6 
was measured by elisa 24 hours later (n=5, mean ± sd).
figure 2. Cytokine responses to Y. enterocolitica, TLR 
and NOD2 ligands
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a. peripheral blood mononuclear cells of the patient with chronic yers-
iniosis and of five control volunteers were exposed to whole Yersinia 
micro-organisms (5 x 104 cfu/ml) or lcrv (5 mg/ml). il-6 concentra-
tions were measured after 24-hour incubation. b. Cytokine responses 
after stimulation with various tlr and nod2 ligands: pam3Cys 
(tlr2, 1 mg/ml), poly i:C (tlr3 50 mg/ml), lps (tlr4, 1 ng/ml), 
flagellin (10 ng/ml) and Mdp (10 mg/ml). il-6 concentrations were 
measured after 24 hours of incubation. 
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genetic studies
To explain the strong defects in specific stimulation with 
flagellin and MDP, we hypothesised that these are due to 
genetic defects in their receptors TLR5 and NOD2. TLR5 
gene was sequenced in both the patient, his three sisters 
and parents. The three most common NOD2 mutations 
known to be associated with a decreased recognition of 
MDP were also determined in the family.
Sequencing showed that the patient possessed TLR5 as 
well as NOD2 variants. The TLR5 gene of the patient 
contained five single nucleotide polymorphisms, three 
of which had already been described, namely A2523G 
(lys-lys), T1846C (phe-leu) and A1775G (asp-ser).18 Two 
new single nucleotide polymorphisms were discovered: 
A1930T (ile-phe) and A2357G (asp-gly). Comparison of the 
human DNA sequence with that of other species (mouse, 
rat, chimpanzee) shows that the A in the 1930 position is 
highly conserved among different species, suggesting this 
is an important residue. The position 2357 is more variable 
(G in other species and A in human). 
The mutations are part of two haplotypes which were 
inherited from his mother (A1930T, A2357G and T1846C) 
and his father (A1775G and A2523G) (figure 3), leading 
to compound heterozygosity for TLR5 in the patient. As 
both chromosomes inherited from his parents contained 
non-synonymous mutations, very likely leading to defects 
in the function of the molecule, it is highly probable 
that the complete incapacity of the cells of the patient to 
respond to flagellin was due to these mutations in the 
TLR5 gene. Interestingly, one sister was also compound 
heterozygous with severely impaired flagellin responses 
(figure 3), whereas the other two sisters were heterozygous 
for mutations inherited either from their mother or their 
father (figure 3). Their cytokine responses, as well as 
those of their parents, were low compared with control 
volunteers, but significantly higher than those of their 
compound heterozygous brother and sister (figure 3).
With regard to the NOD2 mutation, the patient was found 
to be homozygous for the NOD2 3020insC mutation, while 
his parents are heterozygous. One sister was also found to 
be heterozygous for the mutation, whereas the other two 
sisters were homozygous for the wild-type allele (figure 3). 
The 3020insC NOD2 mutation is a well-known mutation 
resulting in a total loss of MDP-recognition capacity.19,20
pro- and anti-inflammatory cytokine responses in patient, 
family and patients with Crohn’s disease and defective 
nod2
Next we investigated production of the pro-inflammatory 
cytokines TNF, IL-17 and the anti-inflammatory cytokine 
IL-10 by PBMC of the patient and the family, when the cells 
were exposed to Y. enterocolitica. As can be seen in figure 
4, the production of TNF and IL-17 by cells of the patient is 
considerably lower than that of family and Crohn’s disease 
patients, whereas IL-10 production is completely normal.
d i s Cus s i on
In this report we present a patient with presumed chronic 
yersiniosis, who was found to have a virtually absent 
pro-inflammatory cytokine response when his cells 
were exposed specifically to Y. enterocolitica. This defect 
was due to the loss of recognition of flagellin by TLR5, 
and the failure to induce a response through NOD2. 
Genetic studies revealed that the patient was compound 
heterozygous for several mutations in the gene coding 
TLR5 (two of which not reported before) and that he was 
homozygous for the 3020insC NOD2 mutation.
It is most likely that the genetic changes in TLR5 led 
to the poor cytokine response to flagellin and strongly 
contributed to the defective response to whole Yersinia. 
Support for this hypothesis is provided by the studies 
that reported an increased susceptibility to another 
facultative intracellular pathogen, Legionella pneumophila, 
in individuals bearing TLR5 mutations that led to 
defective responses to flagellin.18 The contribution of 
the NOD2 3020insC mutation to the lack of response to 
whole Yersinia is unclear. Although we have not found 
an abnormal cytokine response after Y. enterocolitica 
stimulation of cells isolated from Crohn’s disease patients 
homozygous for the 3020insC NOD2 gene mutation 
(figure 4), one could assume synergistic effects between 
NOD2 and TLR5 deficiencies. The synergy between TLR5 
and NOD2, however, is an area of some controversy 
figure 3. Genetic studies in the family of the patient
3020insC NOD2 het
TLR5  A1775G
 A2523G
TRL5 T1846C
 A1930T
 A2537G
3020 NOD2 het
3020insC NOD2 hom
TRL5 A1775G
 A2523G
 T1846C
 A1930T
 A2537G
NOD2 WT
TRL5 T1846C
 A1930T
 A2537G
NOD2 WT
TRL5 A1775G
 A2523G
3020insC NOD2 het
TRL5 T1846C
 A1930T
 A2537G
tlr5 gene was sequenced in both the patient, his three sisters and 
parents. the three most common nod2 mutations known to be asso-
ciated with a decreased recognition of muramyl dipeptide were also 
determined in the family. the mutation analysis identified by sequenc-
ing is presented for both tlr5 and nod2.
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in the literature. In previous studies, we were unable 
to demonstrate significant synergy between these two 
receptor pathways,19 while Van Heel et al. found evidence 
of synergy, albeit to a much lower degree than between 
TLR4 and NOD2.20 Therefore, the data presented here 
point to a more important role of TLR5 for recognition of 
Y. enterocolitica and the disease process.
The finding that our patient was homozygous for the 
3020insC NOD2 mutation, while not having Crohn’s 
disease, is remarkable, since the relative risk for Crohn’s 
disease in individuals bearing this NOD2 genotype is 
up to 42.21 Thus, the first question to be addressed is 
whether the pathology observed is an infiltrate of Crohn’s 
disease. However, the histological picture of the biopsy 
taken after colonoscopy does not support this diagnosis. 
Moreover, the patient had normal stools, did not display 
any other symptoms related to Crohn’s disease, and none 
of the additional investigations have revealed intestinal 
abnormalities. A second possibility would be that the patient 
does not have Crohn’s disease yet, but will still develop the 
disease. Although this cannot be ruled out, it is of interest 
to note that the mean age of diagnosis in ‘genetic’ Crohn’s 
disease is lower than that of common Crohn’s disease.22
Yet another more interesting possibility could be that 
the patient is protected from Crohn’s disease because 
of the concomitant TLR5 defect. Indeed, it has been 
reported that TLR5 mutations are less frequent in Crohn’s 
disease,23 in agreement with the observation that flagellin 
is a dominant antigen in this disease.24 The defective 
production of pro-inflammatory cytokines in our patient, 
albeit most prominent with Yersinia as a stimulant, would 
fit with this observation. Elsewhere, we have defended 
the thesis that a net pro-inflammatory cytokine status 
(with reduced anti-inflammatory response) contributes 
to the development of Crohn’s disease in individuals with 
defective NOD2.17 The recent finding that IL-23 receptor 
polymorphisms protect against Crohn’s disease is in line 
with this concept.25 In addition, recent studies point to 
IL-17 as a key mediator in Crohn’s disease26,27 and in this 
respect our finding of a strongly diminished IL-17 response 
in the patient is of great interest.
In many preclinical studies on chronic yersiniosis, 
a major role for IL-10 has been found, probably due 
to the inhibitory effects of IL-10 on an adequate 
antibacterial effector mechanism mediated through the 
proinflammatory cytokines TNFα, IL-6 and interferon-g.3 
The cytokine production patterns observed in our patient 
closely resemble this situation: Yersinia-induced production 
of proinflammatory cytokines was low, while the IL-10 
production was normal. The production of the latter 
cytokine apparently is not TLR5 and NOD2 dependent. 
In the literature, the virulence factor LcrV acting through 
TLR2 is considered a major stimulant for IL-10 production 
in mice,14 although this is a somewhat controversial issue.28 
In the stimulation assay used in our study LcrV did not 
induce significant amounts of IL-10, neither in our patient 
nor in the controls. Possibly other Yersinia components, 
such as YopH and YopJ/YopP, could also induce IL-10 
induction in human monocytes.28
A potential limitation is that the yersiniosis has merely 
been diagnosed by serology, and therefore the diagnosis 
figure 4. Pro- and anti-inflammatory cytokine responses 
in patient, family and patients with Crohn’s disease and 
defective NOD2 
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the production of the pro-inflammatory cytokines tnf, il-17 and the 
anti-inflammatory cytokine il-10 was assessed by stimulating periph-
eral blood mononuclear cells of the patient and family with Y. enteroco-
litica micro-organisms (5x104 cfu/ml). in addition to the patient, cells 
from the five family members, and four patients with Crohn’s disease 
homozygous for the 3020insC mutation were tested.
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is still presumptive. However, recovering Y. enterocolitica 
from chronic extraintestinal sites has proven extremely 
difficult. It is not unusual in such cases to rely on 
serology,1 although even the Western blot using the 
various Yersinia outer membrane proteins meets with 
some cross-reactivity and false-positives.29 The onset 
of the disease, the development of the abdominal mass 
histologically compatible with a granulomatous infection 
and the gradual response to antibiotics, are strong 
arguments in favour of chronic yersiniosis. 
ConC lus i on
In conclusion, the patient reported here suffered from a 
chronic inflammatory mass due to chronic yersiniosis. The 
finding of mutated genes for TLR5 leading to an almost 
complete loss of response to flagellin puts this patient in 
the category of selective immunodeficiencies.30 This TLR5 
defect also contributes to the lack of proinflammatory 
response to whole Yersinia, while the contributing role of 
the loss of NOD2-induced signals is unclear. In addition, 
it is attractive to speculate that the loss-of-function of TLR5 
is protective against the development of Crohn’s disease in 
this patient homozygous for NOD2 mutations.
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